Carlson Capital L.P. Takes Position in The Clorox Company $CLX

Carlson Capital L.P. acquired a new position in shares of The Clorox Company (NYSE:CLX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 3,700 shares of the company’s stock, valued at approximately $444,000.

Several other large investors also recently added to or reduced their stakes in the stock. Nomura Asset Management Co. Ltd. grew its holdings in Clorox by 9.0% during the 2nd quarter. Nomura Asset Management Co. Ltd. now owns 335,514 shares of the company’s stock valued at $40,285,000 after purchasing an additional 27,639 shares during the last quarter. Simplicity Wealth LLC boosted its position in shares of Clorox by 157.3% during the second quarter. Simplicity Wealth LLC now owns 18,316 shares of the company’s stock valued at $2,199,000 after buying an additional 11,198 shares during the period. Raymond James Financial Inc. boosted its position in shares of Clorox by 15.6% during the first quarter. Raymond James Financial Inc. now owns 269,926 shares of the company’s stock valued at $39,747,000 after buying an additional 36,352 shares during the period. Vise Technologies Inc. bought a new position in shares of Clorox during the second quarter valued at approximately $328,000. Finally, Nuance Investments LLC raised its holdings in shares of Clorox by 182.5% in the second quarter. Nuance Investments LLC now owns 848,106 shares of the company’s stock worth $101,832,000 after buying an additional 547,839 shares during the period. 78.53% of the stock is owned by institutional investors.

Clorox Stock Performance

CLX opened at $107.75 on Thursday. The company has a market cap of $13.14 billion, a P/E ratio of 16.53, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15. The firm’s 50-day moving average price is $114.23 and its 200-day moving average price is $121.67. The Clorox Company has a 52-week low of $98.20 and a 52-week high of $171.37.

Clorox (NYSE:CLX) last issued its earnings results on Monday, November 3rd. The company reported $0.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.07. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The company had revenue of $1.43 billion during the quarter, compared to analyst estimates of $1.41 billion. During the same quarter last year, the business posted $1.86 EPS. The firm’s quarterly revenue was down 18.9% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. As a group, equities analysts anticipate that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Wednesday, January 28th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 4.6%. The ex-dividend date of this dividend is Wednesday, January 28th. Clorox’s dividend payout ratio is presently 77.86%.

Insider Transactions at Clorox

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the transaction, the chief operating officer owned 54,221 shares of the company’s stock, valued at $6,711,475.38. This represents a 21.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Pierre R. Breber acquired 4,000 shares of the business’s stock in a transaction on Friday, November 21st. The stock was acquired at an average price of $104.13 per share, with a total value of $416,520.00. Following the acquisition, the director owned 13,000 shares in the company, valued at $1,353,690. The trade was a 44.44% increase in their position. The SEC filing for this purchase provides additional information. 0.63% of the stock is owned by company insiders.

Analysts Set New Price Targets

CLX has been the subject of several research analyst reports. BNP Paribas Exane decreased their target price on Clorox from $110.00 to $103.00 and set an “underperform” rating for the company in a research report on Tuesday, November 4th. Zacks Research lowered shares of Clorox from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 28th. Barclays lowered their price objective on shares of Clorox from $112.00 to $108.00 and set an “underweight” rating for the company in a research report on Tuesday, November 4th. Jefferies Financial Group reaffirmed a “buy” rating and set a $152.00 target price on shares of Clorox in a research report on Tuesday, November 4th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on Clorox from $128.00 to $121.00 and set a “hold” rating for the company in a report on Tuesday, November 4th. One research analyst has rated the stock with a Buy rating, twelve have issued a Hold rating and five have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $125.69.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.